EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells

Priyanka Gadam Rao iD, Gregory S Lambert iD, Chitra Upadhyay iD

Journal of Virology · 2023

DOI: 10.1128/jvi.00710-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2023. Verfasst von Priyanka Gadam Rao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York, USA. Hauptthemen laut MEDLINE: Broadly Neutralizing Antibodies, HIV Antibodies, HIV Infections, HIV-1. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The envelope (Env) glycoproteins on HIV-1 virions are the sole target of broadly neutralizing antibodies (bNAbs) and the focus of vaccines. However, many cross-reactive conserved epitopes are often occluded on virus particles, contributing to the evasion of humoral immunity. This study aimed to identify the Env epitopes that are exposed/occluded on HIV-1 particles and to investigate the mechanisms contributing to their masking. Using a flow cytometry-based assay, three HIV-1 isolates, and a panel of antibodies, we show that only select epitopes, including V2i, the gp120-g41 interface, and gp41-MPER, are accessible on HIV-1 particles, while V3, V2q, and select CD4bs epitopes are masked. These epitopes become accessible after allosteric conformational changes are induced by the pre-binding of select Abs, prompting us to test if similar conformational changes are required for these Abs to exhibit their neutralization capability. We tested HIV-1 neutralization where the virus-mAb mix was pre-incubated/not pre-incubated for 1 hour prior to adding the target cells. Similar levels of neutralization were observed under both assay conditions, suggesting that the interaction between virus and target cells sensitizes the virions for neutralization via bNAbs. We further show that lectin-glycan interactions can also expose these epitopes. However, this effect is dependent on the lectin specificity. Given that, bNAbs are ideal for providing sterilizing immunity and are the goal of current HIV-1 vaccine efforts, these data offer insight on how HIV-1 may occlude these vulnerable epitopes from the host immune response. In addition, the findings can guide the formulation of effective antibody combinations for therapeutic use. IMPORTANCE The human immunodeficiency virus (HIV-1) envelope (Env) glycoprotein mediates viral entry and is the sole target of neutralizing antibodies. Our data suggest that antibody epitopes including V2q (e.g., PG9, PGT145), CD4bs (e.g., VRC01, 3BNC117), and V3 (2219, 2557) are masked on HIV-1 particles. The PG9 and 2219 epitopes became accessible for binding after conformational unmasking was induced by the pre-binding of select mAbs. Attempts to understand the masking mechanism led to the revelation that interaction between virus and host cells is needed to sensitize the virions for neutralization by broadly neutralizing antibodies (bNAbs). These data provide insight on how bNAbs may gain access to these occluded epitopes to exert their neutralization effects and block HIV-1 infection. These findings have important implications for the way we evaluate the neutralizing efficacy of antibodies and can potentially guide vaccine design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Broadly Neutralizing AntibodiesHIV AntibodiesHIV InfectionsHIV-1Epitopes, B-LymphocyteHost Microbial InteractionsHumansAntibodies, MonoclonalHIV Envelope Protein gp120LectinsAIDS VaccinesVirionPolysaccharides

Stichwörter der Autor:innen

antibodiesbroadly neutralizing antibodies (bNAbs)envelope conformationsglycansglycosylationhuman immunodeficiency viruslectinsneutralizationnon-neutralizing antibodies (nNAbs)

Substanzen

Antibodies, MonoclonalBroadly Neutralizing AntibodiesHIV AntibodiesHIV Envelope Protein gp120LectinsEpitopes, B-LymphocyteAIDS VaccinesPolysaccharides

Autor:innen und Institutionen

  • Division of Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York, USA.

ORCID-Profile: Priyanka Gadam Rao, Gregory S Lambert, Chitra Upadhyay

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Rao, P. G., Lambert, G. S., & Upadhyay, C. (2023). Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells. Journal of Virology. https://doi.org/10.1128/jvi.00710-23

Vancouver

Rao PG, Lambert GS, Upadhyay C. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells. Journal of Virology. 2023. doi:10.1128/jvi.00710-23

BibTeX
@article{Rao2023,
  author = {Rao, Priyanka Gadam and Lambert, Gregory S and Upadhyay, Chitra},
  title = {Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells},
  journal = {Journal of Virology},
  year = {2023},
  doi = {10.1128/jvi.00710-23}
}
Kostenlos starten →